Skip to Main Content

investment

  • sam patrick posted an article
    Addressing high demand for accomplished leaders to spearhead the sector’s growth. see more

    Compliments of Investment Monitor

    The life sciences industry in Charleston is growing fast. As more and more businesses and professionals are drawn towards the area, there is high demand for accomplished leaders to spearhead the sector’s growth.

    Executive search consultant Joyce De Leo is doing her part to find these individuals. She spent a 25-year career researching and teaching medicine at esteemed institutions in the north-eastern US, earning a PhD in neuropharmacology, and establishing a start-up pharmaceuticals company focused on treating chronic pain. She now works for executive search company WittKieffer, where she recruits talent for high-level leadership roles in healthcare and academic medicine. Last year, De Leo relocated from Boston to Charleston after falling in love with the region and recognising its rich opportunities for market growth. Read the rest of this article by clicking here.

  • sam patrick posted an article
    Provides Kyocera AVX with opportunities to further support flourishing tech industry, life sciences see more

    A manufacturer of advanced electronic components headquartered in Fountain Inn, Kyocera AVX, has invested in an early stage venture capital firm to complement its research and development programs and support innovation in the medical technology industry.

    Good Growth Capital (GGC), a majority women-owned venture capital firm based in Charleston with offices in Boston, Mass., typically invests in complex science and deep-tech startups. The partnership was established in August and announced in a news release on Nov. 29.

    “This investment provides Kyocera AVX with abundant opportunities to further support the flourishing tech industry both here in the Carolinas and nationwide by investing through GGC and exploring co-investments,” company CEO Johnny Sarvis said in the release.

    Kyocera AVX has more than 30 research, design, manufacturing and customer support facilities in 16 countries. It invests in research and development and submits several patent applications annually, according to its website.

    The company manufactures products for the automotive, industrial, medical, military, consumer electronics, communications and transportation markets. For the medical industry, the company creates products for devices such as pacemakers, cochlear implants and diagnostics equipment.

  • sam patrick posted an article
    Cancer testing innovator KIYATEC fits investor’s focus in disruptive healthcare technology see more

    KIYATEC, Inc. announced today that it secured a $2.5 million investment from Boston-based healthcare service and technology venture capital fund Seae Ventures. The fund’s focus in disruptive healthcare technologies aligns with KIYATEC’s goal to fundamentally change the way cancer drugs are selected by providing oncologists with patient-specific evidence of response, prior to treatment initiation.

    Although significant strides toward personalized medicine have been achieved in the past two decades, oncologists remain largely unable to predict treatment response for individual patients. As a result, many patients receive ineffective drug therapies, while unnecessarily experiencing toxic side effects and shouldering high cost of treatment. KIYATEC’s 3D-Predict platform and associated tests increase the patient-centric value of cancer drugs by informing oncologists’ pre-treatment cancer drug selection. Importantly, the platform also aids pharmaceutical companies by improving decision-making across drug lifecycles.

    “We are grateful for Seae Venture’s ’yes’ to KIYATEC and welcome the addition of their managing partner, Jason Robart, to our board of directors. The fund’s healthcare industry relationships coupled with Jason’s personal experience with health insurance innovation will be beneficial as we implement our strategy to impact those who need it most – cancer patients and their providers,” said Matthew Gevaert, CEO and co-founder of KIYATEC.

    The investment comes on the heels of other recent announcements of success for KIYATEC. The first release of the 3D-PREDICT clinical study data in late 2020, combined with the more recent March 2021 publication demonstrating platform expansion into immuno-oncology, highlight the rapid and disruptive nature of KIYATEC’s progress. The company’s platform has been shown to be clinically predictive for patient-specific response to chemotherapy and targeted agents, and it has been analytically validated in both ovarian cancer and high-grade gliomas.

    Robart said, “KIYATEC has the potential to significantly improve outcomes for patients and their providers, not just for one cancer type, but across many solid tumors. We’re excited about the science, the team and the potential. We welcome KIYATEC into our portfolio of companies and I’m thrilled to join its board of directors.”

     

    About KIYATEC

    KIYATEC leverages its proprietary ex vivo 3D cell culture platforms to accurately model and predict response to approved and investigational cancer drugs targeting a spectrum of solid tumors. The platforms are positioned to address the gap-defining limitations of current cancer drug selection. The company’s Clinical Services business is currently engaged in the validation of clinical assays as well as investigator-initiated studies in ovarian cancer, breast cancer, glioblastoma and rare tumors, in its CLIA-certified laboratory. The company’s Drug Development Services business works in partnership with leading biopharmaceutical companies to unlock response dynamics for their investigational drug candidates across the majority of solid tumor types.

  • sam patrick posted an article
    Good news for investment opportunities in the Palmetto State see more

    Compliments of Columbia Business Report

    South Carolina’s General Assembly renewed the 2013 High Growth Small Business Job Creation or “Angel Investor” Act earlier this week until 2025.

    The act offers tax credits of up to 35% of the investment to start-up investors, according to a recent announcement from the S.C. State Secretary Mark Hammond. Hammond’s office, which approves all businesses for the program.

    “Since the High Growth Small Business Job Creation Act originally passed, nearly 300 companies have registered as qualified businesses, with over 90 registered at the end of 2019,” Hammond, said in the release. “Furthermore, these qualified businesses have reported creating over 1,200 full-time, part-time and temporary jobs. I am thrilled that our state has continued this program that promotes innovation and entrepreneurship, especially during this time of economic uncertainty.”

    Qualifying businesses must be a corporation, limited liability company, general or limited partnership headquartered in South Carolina with 25 or fewer employees and a gross income of $2 million or less, according to the release.

    Program preference is extended to certain types of enterprises within the manufacturing, processing, warehousing, wholesaling, software development, information technology service, research and development, and health care sectors.